Table 1.

Patients with a decrease in MLH1 or MSH2 expression and other molecular markers

No.MLH1MSH2CIN*CAAurora-A overexpressionIncreased p53 immunoreactivityFluorescence in situ hybridization 20q13 gainLSC ploidyRecurrence (mo)§Progression (mo)
1NLD− (94)− (94)
2NLD+ (20)− (89)
3LND+ (79)− (81)
4LND− (62)− (62)
5LLD+ (23)− (59)
6LND− (39)− (39)
7LND+ (4)− (18)
8NLD− (8)− (8)
9LLD− (6)− (6)
  • Abbreviation: N, normal expression; L, low expression, LSC, laser scanning cytometer. D, diploid; A, aneuploid.

  • * More than 25% of the average variant fractions of chromosome 7, 9, and 17.

  • CA, centrosome amplification; >5% of cells with ≥3 centrosomes per cell.

  • 20q13 gain: >60% of cells had more than five signals per cell for 20q13.

  • § Time in months from operation to tumor recurrence or last follow-up.